Prestige Consumer Healthcare (PBH) 8-K Prestige Brands, Inc. Announces Offering of $290 Million Senior Notes

Exhibit 99.2

UNAUDITED PRO FORMA COMBINED FINANCIAL DATA

The following tables which have been prepared in accordance with GAAP, except GSK Brands data, which have been prepared in accordance with IFRS, set forth unaudited pro forma combined financial data as of September 30, 2011 and for the fiscal year ended March 31, 2011, for the nine months ended September 30, 2011 and the twelve months ended September 30, 2011. The unaudited pro forma balance sheet as of September 30, 2011 gives effect to the Transactions as if they had occurred on that date. The unaudited pro forma combined statement of operations for the fiscal year ended March 31, 2011, for the nine months ended September 30, 2011 and the twelve months ended September 30, 2011 have been prepared to illustrate the effects of the Transactions, as if they had occurred at the beginning of the respective periods. The pro forma data has been derived from the audited financial statements of Prestige for the fiscal year ended March 31, 2011, the unaudited financial statements of Prestige for the six months ended September 30, 2010 and September 30, 2011, the unaudited financial statements for the nine months ended December 31, 2010, the audited financial statements of the GSK Brands for the fiscal year ended December 31, 2010 and the unaudited financial statements of the GSK Brands for the nine months ended September 30, 2010 and 2011. For purposes of the pro forma combined financial information for the nine months ended September 30, 2011, the unaudited financial statements of Prestige for the three months ended March 31, 2011 were combined with the unaudited financial statements of Prestige for the six months ended September 30, 2011. The GSK Brands have historically used a December 31 fiscal year end. For purposes of the pro forma combined financial information for the fiscal year ended March 31, 2011 herein, the historical December 31, 2010 period was used for the GSK Brands. The pro forma balance sheet as of September 30, 2011 gives effect to the Transactions as if they had occurred on that date. Additionally, the acquisition of the Blacksmith brands and theDramamine asset acquisition have been included as if the business and assets were acquired by Prestige at the beginning of the respective periods.

The unaudited pro forma combined financial data and accompanying notes are provided for informational purposes only and are not necessarily indicative of the operating results that would have occurred had the Transactions been consummated prior to April 1, 2010, nor are they necessarily indicative of our future results of operations.

Certain pro forma adjustments were based on a preliminary assessment of the value of tangible and intangible assets acquired as part of the Acquisition. However, changes to adjustments included in the pro forma consolidated financial data are expected as valuations of assets and liabilities are finalized and additional information is available. The final purchase price allocations for the Acquisition will be based on a formal valuation analysis by an outside appraisal firm and may include an adjustment to the amounts recorded for the value of inventory, identifiable intangible assets and goodwill. Final valuations will be obtained after the completion of the Acquisition.

The adjustments to the unaudited pro forma combined financial data are based upon available information and certain assumptions that we believe are reasonable and exclude certain non-recurring charges that will be incurred in connection with the Transactions and recognized in the twelve months following, including: (1) amortization of estimated inventory fair value step-up of approximately $2 million expected to impact the cost of sales in fiscal year 2013; (2) the estimated costs of approximately $3 million related to the integration of the GSK Brands and Prestige; and (3) the write-off of deferred financing charges in connection with our Existing Term Loan Facility of approximately $3 million.

The following information should be read in conjunction with the “Capitalization,” “Unaudited Pro Forma Combined Financial Data,” “Selected Historical Financial and Other Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Prestige,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations of the GSK Brands,” and the financial statements and notes thereto included elsewhere in this offering memorandum.

1

Prestige Brands Holdings, Inc. and Subsidiaries

Unaudited Pro Forma Combined Balance Sheet

As of September 30, 2011

(in thousands)	Prestige		GSK Brands (IFRS)		Adjustments Related to the Transactions(a)			Pro Forma
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	7,961	$	—	$	(7,961	)(a)	$	—
Net receivables		49,445		—		—			49,445
Inventories		46,408		14,986		2,200	(b)		63,594
Prepaid expenses		3,018		—		—			3,018
Deferred income taxes		5,549		—		—			5,549
Total current assets		112,381		14,986		(5,761	)		121,606
Long-term assets:
Net, property plant and equipment		1,379		—		—			1,379
Goodwill		153,696		—		—			153,696
Intangible assets		781,615		211,303		431,511	(b)		1,424,429
Other long-term assets		6,070		—		26,300	(a)		32,370
Total assets	$	1,055,141	$	226,289	$	452,050		$	1,733,480
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	25,184	$	—	$	—		$	25,184
Accrued expenses		28,730		—		—			28,730
Current portion of long term debt		—		—		24,839			24,839
Income taxes payable		2,217		—		—			2,217
Total current liabilities		56,131		—		24,839			80,970
Long-term liabilities:
Long-term debt		447,403		—		670,800	(a)		1,118,203
Deferred income Tax		160,152		—		—			160,152
Total liabilities		663,686		—		695,639			1,359,325
Total stockholders’ equity		391,455		226,289		(243,589	)(c)		374,155
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	1,055,141	$	226,289	$	452,050		$	1,733,480

See accompanying notes to the unaudited pro forma combined statement of operations.

2

(a) The unaudited pro forma combined balance sheet gives effect to the following pro forma adjustments and reflects incurrence of debt, payment of acquisition consideration to GSK, repayment of historical debt, and fees and expenses incurred in connection with the acquisition of the GSK Brands, all presented as if they occurred on September 30, 2011.

Source of funds (in thousands)
New Senior Secured Credit Facilities(1):
New Term Loan Facility(2)		620,000
New ABL Revolving Credit Facility(2)		39
Existing Cash on Balance Sheet		7,961
Notes offered hereby(3)		290,000
Total source of funds	$	918,000
Use of funds (in thousands)
Purchase price(4)		660,000
Existing Senior Secured Credit Facilities(2)(5)		202,000
Fees and expenses(6)		56,000
Total use of funds	$	918,000

(1) The New Senior Secured Credit Facilities will consist of (i) the $620 million New Term Loan Facility with a seven-year maturity and (ii) the $50 million New ABL Revolving Credit Facility with a five-year maturity.

(2) The Existing Senior Secured Credit Facilities had a principal amount outstanding at December 31, 2011 of $184 million. Accordingly, we do not expect to be drawn under the New ABL Revolving Credit Facility at the closing of the Transactions.

(3) Represents the principal amount of the notes offered hereby, excluding any original issue discount.

(4) Represents cash paid, based upon the estimated purchase price of the assets of the GSK Brands, subject to a purchase price adjustment, if any, based on the value of inventory delivered upon the consummation of the Acquisition. The purchase price reflected above represents our estimate of the purchase price and adjustments as of the consummation of the Acquisition.

(5) Based upon the aggregate principal amount outstanding as of September 30, 2011 of the Existing Senior Secured Credit Facilities. At September 30, 2011, the average interest rate on the Existing Senior Secured Credit Facilities was 4.75%.

(6) Represents estimated fees and expenses payable by us associated with the Transactions, of which $29 million ($26 million net of existing debt issuance costs to be written off) relates to debt issuance costs to be capitalized and $12 million relates to expected original issue discount.

(b) Assumes the acquisition of the GSK Brands had been consummated on September 30, 2011 and was accounted for as a purchase in accordance with ASC 805, “Business Combinations.” Under purchase accounting, the estimated acquisition consideration is allocated to assets and liabilities based on their relative fair values. The pro forma adjustments are based upon a preliminary assessment of value and will be adjusted when valuations are finalized.

Total acquisition consideration allocation (in thousands)
Consideration paid to GSK		660,000
Less book value of assets acquired		226,289
Step-up to be allocated	$	433,711
Preliminary allocation (in thousands)
Inventory		2,200
Identifiable intangible assets		431,511
Preliminary allocation	$	433,711

(c) Represents the elimination of equity accounts for the GSK Brands upon the application of purchase accounting and certain expenses payable by us associated with the Transactions, which were not capitalized.

3

Prestige Brands Holdings, Inc. and Subsidiaries

Unaudited Pro Forma Combined Statement of Operations

Fiscal Year Ended March 31, 2011

(in thousands)	Prestige			GSK Brands (Fiscal Year Ended December 31, 2010)			Blacksmith Acquisition Adjustments			Dramamine Acquisition Adjustments			Adjustments Related to the Transactions			Combined Pro Forma for the Transactions Fiscal Year Ended March 31, 2011(a)
Net sales	$	333,715		$	207,342		$	56,476	(e)	$	13,945	(e)	$	—		$	611,478
Other revenue		2,795			—			—			—			—			2,795
Total revenue		336,510			207,342			56,476			13,945			—			614,273
Cost of revenue		165,632			64,676			26,318	(e)		4,441	(e)		—			261,067
Gross profit		170,878			142,666			30,158			9,504			—			353,206
Advertising and promotional expenses		42,897			36,721			4,592	(e)		—			—			84,210
General and administrative expenses		41,960			22,998			839	(e),(f)		(508	)(f)		(219	)		65,070
Amortization of intangibles		9,876			10,311			284	(b)		—	(b)		(7,335	)(b)		13,136
Total operating expenses		94,733			70,030			5,715			(508	)		(7,554	)		162,416
Operating income		76,145			72,636			24,443			10,012			7,554			190,790
Interest expense, net		27,317			—			3,908	(c)		—			61,069	(c)		92,294
Other non—operating income (expense)		(300	)		(295	)		—			—			—			(595	)
Total other expenses		27,617			295			3,908			—			61,069			92,889
Pre—tax income		48,528			72,341			20,535			10,012			(53,515	)		97,901
Provision for income taxes		19,349			—			8,214	(d)		4,005	(d)		7,530	(d)		39,098
Income (loss) from continuing operations		29,179			72,341			12,321			6,007			(61,045	)		58,803
Income (loss) from discontinued operations, net of income tax		591			—			—			—			—			591
Loss on sale of discontinued operations, net of income tax		(550	)		—			—			—			—			(550	)
Net income	$	29,220		$	72,341		$	12,321		$	6,007		$	(61,045	)	$	58,844

See accompanying notes to the unaudited pro forma combined statement of operations.

4

Prestige Brands Holdings, Inc. and Subsidiaries

Unaudited Pro Forma Combined Statement of Operations

Nine Months Ended September 30, 2011

	Nine Months Ended September 30, 2011					Blacksmith Acquisition Adjustments		Dramamine Acquisition Adjustments			Adjustments Related to the Transactions			Combined Pro Forma for the Transactions Nine Months Ended September 30, 2011(a)
(in thousands)	Prestige		GSK Brands
Net sales	$	294,508	$	156,864		$	—	$	—	(e)	$	—		$	451,372
Other revenue		2,694		—			—		—			—			2,694
Total revenue		297,202		156,864			—		—			—			454,066
Cost of revenue		147,123		49,858			—		—	(e)		—			196,981
Gross profit		150,079		107,006			—		—			—			257,085
Advertising and promotional expense		37,428		28,709			—		—			—			66,137
General and administrative		29,730		18,499			—		(508	)(f)		(164	)		47,557
Amortization of intangibles		7,660		413			—		—	(b)		2,508			10,581
Total operating expenses		74,818		47,621			—		(508	)		2,344			124,275
Operating income		75,261		59,385			—		508			(2,344	)		132,810
Interest expense, net		25,666		—			—		—			42,828	(c)		68,494
Other non—operating income (expense)		5,063		58			—		—			—			5,121
Total other expense		20,603		(58	)		—		—			42,828			63,373
Pre—tax income		54,658		59,443			—		508			(45,172	)		69,437
Provision for income taxes		20,527		—			—		203	(d)		5,708	(d)		26,438
Income (loss) from continuing operations		34,131		59,443			—		305			(50,880	)		42,999
Income (loss) from discontinued operations, net of income tax		—		—			—		—			—			—
Loss on sale of discontinued operations, net of income tax		—		—			—		—			—			—
Net income	$	34,131	$	59,443		$	—	$	305		$	(50,880	)	$	42,999

See accompanying notes to the unaudited pro forma combined statement of operations.

5

Prestige Brands Holdings, Inc. and Subsidiaries

Unaudited Pro Forma Combined Statement of Operations

Last Twelve Months Ended September 30, 2011

	Twelve Months Ended September 30, 2011					Blacksmith Acquisition Adjustments			Dramamine Acquisition Adjustments			Adjustments Related to the Transactions			Combined Pro Forma for the Transactions Twelve Months Ended September 30, 2011(a)
(in thousands)	Prestige		GSK Brands
Net sales	$	384,584	$	206,713		$	9,907	(e)	$	3,431	(e)	$	—		$	604,635
Other revenue		3,226		—			—			—			—			3,226
Total revenue		387,810		206,713			9,907			3,431			—			607,861
Cost of revenue		193,719		66,738			5,536	(e)		1,280	(e)		—			267,273
Gross profit		194,091		139,975			4,371			2,152			—			340,588
Advertising and promotional expense		50,477		36,935			1,116	(e)		—			—			88,528
General and administrative		45,156		23,182			(5,102	)(e),(f)		(508	)(f)		(219	)		62,509
Amortization of intangibles		10,173		10,311			41	(b)		—	(b)		(7,335	)		13,190
Total operating expenses		105,806		70,428			(3,945	)		(508	)		(7,554	)		164,227
Operating income		88,285		69,547			8,316			2,659			(7,554	)		176,361
Interest expense, net		33,340		—			558	(c)		—			58,396	(c)		92,294
Other non—operating income (expense)		5,063		(334	)		—			—			—			4,729
Total other expense		28,277		334			558			—			58,396			87,565
Pre—tax income		60,008		69,213			7,558			2,659			(50,842	)		88,796
Provision for income taxes		23,731		—			3,103	(d)		1,064	(d)		7,348	(d)		35,246
Income (loss) from continuing operations		36,277		69,213			4,655			1,595			(58,190	)		53,550
Income (loss) from discontinued operations, net of income tax		32		—			—			—			—			32
Loss on sale of discontinued operations, net of income tax		—		—			—			—			—			—
Net income	$	36,309	$	69,213		$	4,655		$	1,595		$	(58,190	)	$	53,582

See accompanying notes to the unaudited pro forma combined statement of operations.

6

Prestige Brands Holdings, Inc. and Subsidiaries

Notes to the Unaudited Pro Forma Combined Statement of Operations

(dollars in thousands)

(a) The unaudited pro forma consolidated financial statements have been prepared to reflect the asset acquisition ofDramamine and the application of purchase accounting under ASC 805, “Business Combinations,” for the acquisitions of the Blacksmith brands and the GSK Brands. The unaudited pro forma combined statement of operations for the fiscal year ended March 31, 2011, for the nine months ended September 30, 2011, and the twelve months ended September 30, 2011 have been prepared to illustrate the effects of the Transactions, the acquisitions of the Blacksmith brands and the acquisition of theDramamine assets as if they had occurred at the beginning of each respective period. The GSK Brands have historically used a December 31 fiscal year end. For purposes of the fiscal year ended March 31, 2011 data presented herein, a historical December 31, 2010 period was used for the GSK Brands.

(b) These adjustments represent the amortization expense related to the purchase price and amortizable intangible assets for the acquisition of the Blacksmith brands, the acquisition of theDramamine assets and the GSK Brands. The expenses associated with the GSK Brands have been estimated based upon the following assumptions:

(in thousands)	Annual Estimate
Preliminary allocation:
Inventory	$	17,186
Brand intangibles—non-amortizable		589,803
Brand intangibles—amortizable		53,011
Illustrative consideration	$	660,000
Amortization of intangibles:
Total acquired intangibles	$	632,177
Non-amortizable intangibles		589,803
Amortizable intangibles		53,011
Estimated useful life		19
Pro forma amortization	$	2,757

Incremental amortization expenses related to the amortizable intangible assets have been included for the acquisition of the Blacksmith brands because our reported amortization expenses for the fiscal year ended March 31, 2011 included five months of amortization expense for the acquisition of the Blacksmith brands. The acquisition of the Blacksmith brands was completed on November 1, 2010. Accordingly, the pro forma adjustments for the fiscal year ended March 31, 2011 represents an additional seven months of amortization expense and the pro forma adjustments for the twelve months ended September 30, 2011 represents an additional one month of amortization expense. TheDramaminebrand was assigned an indefinite life and as such there is no pro forma adjustment for the amortization expense related to theDramamine asset acquisition.

7

(c) Reflects the interest expense as a result of the acquisition of the GSK Brands, which is calculated as follows:

(in thousands)	Fiscal Year Ended March 31, 2011			Nine Months Ended September 30, 2011			Twelve Months Ended September 30, 2011
Total cash interest from the debt requirements of the Transaction (1)	$	85,985		$	63,762		$	85,985
Amortization of deferred financing costs (2)		6,309			4,732			6,309
Total pro-forma interest expense	$	92,294			68,494		$	92,294
Less: Historical interest expense		(27,317	)		(25,666	)		(33,340	)
Less: Pro forma interest for the Blacksmith Acquisition		(3,908	)		—			(558	)
Net adjustment to interest expense	$	61,069		$	42,828		$	58,396

(1) Represents the interest on the outstanding and unused balance on the New Senior Secured Credit Facilities (variable rate), the 2018 Senior Notes, and the notes offered hereby, together assuming a weighted average interest rate of 7.8%. An increase (decrease) of 25 basis points in the assumed interest rate would result in an increase (decrease) of $2.9 million per year in total interest expense.

(2) Represents annual amortization expense on estimated $32.4 million of deferred financing fees, utilizing a weighted average maturity of 7.1 years, which approximates amortization under the effective interest rate method.

(d) Reflects the tax effect of the pro forma adjustments and the pro forma impact of inclusion of a tax provision for the operating results of the GSK Brands, each at an estimated 40% effective tax rate.

(e) The acquisition of the Blacksmith brands and theDramamineasset acquisition were completed on November 1, 2010 and January 6, 2011, respectively. This adjustment records the impact to revenue and expenses as if these acquisitions occurred on April 1, 2010 (the first day of our fiscal year ended March 31, 2011).

(f) In conjunction with the acquisition of the Blacksmith brands and theDramamineasset acquisition, we incurred certain costs that were specific to each of the respective transactions (e.g., banker and professional fees), and these costs have been removed as a pro forma adjustment.

8